trial
as of 2026-07-01A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
NCTId NCT03044249
at a glance
Phase 2 · Terminated
Enrollment 81 (actual)
Sponsored by Mediti Pharma Inc.
Primary completion 2020-01-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Terminated
Enrollment
81 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2017-05-04
Primary completion
2020-01-30
Eligibility
ALL · 50 Years
Interventions & indications
Sponsors
Mediti Pharma Inc.Lead Sponsor
Sites
20 total
Phoenix, United StatesPasadena, United StatesFairfield, United StatesBoca Raton, United StatesBrooksville, United StatesHialeah, United StatesMiami Springs, United StatesOrlando, United StatesPort Charlotte, United StatesSt. Petersburg, United StatesTampa, United StatesOverland Park, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
81
Phase
PHASE2
Primary Completion Date
2020-01-30
Status
TERMINATED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication